Objective There is growing interest in the use of transcranial sonography (TCS) 
Introduction

In 1995, Becker and colleagues first reported hyperechogenicity of the substantia nigra (SN) by transcranial sonography (TCS) in patients with Parkinson's disease (PD)
. Since then, there has been continued research on this finding, both clinically and experimentally (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . The diagnosis of PSP was made in accordance with the NINDS criteria (13) . The clinical diagnosis of MSA was made in accordance with the consensus criteria for probable MSA (14) . The diagnosis of ET was made on the basis of the Tremor Investigation Group Criteria (15) . All patients provided informed consent.
T a b l e 1 . De mo g r a p h i c Da t a o f P a t i e n t s S t u d i e d
Transcranial sonography
TCS was performed by using a conventional transcranial Doppler sonographer equipped with a 2.5 MHz phased array transducer (Aplio ® , Toshiba Medicals, Japan). TCS was performed in subjects lying in a supine position. Ultrasound scanning was performed through bilateral acoustic bone window using standard techniques as described previously (9) (10) (11) 
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Results
Accessibility of SN in Japanese subjects
There was a high rate of recording failure of the SN, judged as grade C, in Japanese subjects (Fig. 2) 
SN hyperechogenicity in parkinsonism
The rates of SN hyperechogenicity in diseased and control subjects in whom the SN was assessable are demonstrated in Fig. 3 (Fig. 3) .
There was no correlation between the degree of SN hyperechogenicity and disease stage (Hoehn-Yahr stage; P=0.449), or the degrees of SN hyperechogenicity and duration of illness (P=0.426). In other neurological disorders, the frequencies of SN hyperechogenicity were generally low, as follows: PSP (1/13; 8%); MSA (1/11; 9%); ET (0/13; 0%). The frequency of SN hyperechogenicity in each disease state did not significantly differ to that of healthy controls (1/15; 7%).
Discussion
The present study showed that 83% of subjects who were clinically diagnosed as having PD had SN hyperechogenic-ity. In comparison, one of 15 healthy subjects (7%) had SN hyperechogenicity. These findings were similar to those of previously published reports demonstrating that SN hyperechogenicity was present in 81% to 100% of examined PD patients (2) , and in less than 10% of control subjects (6 (19, 20 
